– December 1, 2012
December 1, 2012
View Issues
-
Trastuzumab and the Risk of Congestive Heart Failure
This retrospective cohort study of 12,500 women with breast cancer, treated in the community, compared the incidence of congestive heart failure in those who received trastuzumab-containing adjuvant chemotherapy regimens with those who did not. There was a four-fold increase in the risk of heart failure in women who received trastuzumab alone and a seven-fold increase in those who received anthracycline plus trastuzumab. -
PET/CT SUV of Prognostic Value in Metastatic Breast Cancer
By examining a large series of patients who had PET/CT scans obtained within 2 months of diagnosis of metastatic breast cancer, it was discovered that site-specific SUV correlated with survival. This was most apparent and statistically significant when comparing survival for patients with bone metastases, although similar but not statistically significant data also were presented for patients with liver, lung, or lymph node involvement. -
Postoperative Management of GIST
A 61-year-old nuclear engineer with a past history of hypertension was admitted through the emergency department because of persistent lower abdominal pain. Clinical picture and imaging studies initially pointed to pelvic abscess. -
Watchful Waiting for Patients with Follicular Lymphoma: Even in the Rituximab Era
In an analysis of a well-characterized dataset capturing outcomes for patients with asymptomatic, low-burden follicular lymphoma, those managed by initial watchful waiting had outcomes similar to comparable patients who were treated at the time of diagnosis with regimens including rituximab. Thus, delayed initial therapy remains a reasonable approach for selected follicular lymphoma patients. -
Clinical Considerations for Uterine Serous Cancer
Uterine (papillary) serous cancer is a genomically unstable cancer associated with poor survival even in stage i. it is also frequently associated with a secondary malignancy, particularly breast cancer. Comprehensive surgical staging is recommended since extrauterine disease can be present without other high-risk uterine features, like myometrial invasion. However, an optimal adjuvant treatment protocol remains to be defined. -
Pharmacology Watch: Menopausal Hormone Therapy and the Risk for VTE, AD
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions. -
Clinical Briefs in Primary Care Supplement